Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

img_004.jpg

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies

Radiotherapy as a tool to elicit clinically actionable signalling

Lapatinib and lapatinib plus trastuzumab therapy versus

Lapatinib and lapatinib plus trastuzumab therapy versus

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies

Early Adverse Events predict Survival Outcomes in HER2-positive

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast

Clinical management of cutaneous adverse events in patients on

Page 1526 – Cancer Therapy Advisor

Neoadjuvant Therapy in HER2-Positive Breast Cancer: Ready for

Therapeutic vaccines for breast cancer: Has the time finally come

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies

Everolimus and its role in hormone-resistant and trastuzumab

Page 1597 – Cancer Therapy Advisor